Prelude Therapeutics Incorporated Share Price & Technical Analysis
PRLD · $4.12 (-3.51%)
Healthcare / Biotechnology
$4.12
-3.51%
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced br…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-17% return in May, -7% avg return in past 3 year May month.
70% return in 2026, 34% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -34% | 47% | 26% | 49% | -17% | – | – | – | – | – | – | – | 70% |
| 25 | -15% | -27% | 14% | 25% | -10% | -11% | 0% | 50% | 17% | 7% | 6% | 71% | 126% |
| 24 | -23% | 34% | 9% | -21% | 3% | -3% | 68% | -19% | -60% | -40% | -17% | 18% | -49% |
| 23 | 7% | -12% | -2% | 12% | -12% | -20% | -13% | -3% | -16% | -45% | 94% | 34% | 24% |
| 22 | -21% | -11% | -21% | -33% | -9% | 21% | -6% | 47% | -8% | 0% | -3% | -12% | -55% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$367.15M
P/E ratio
—
52W high
$5.54
52W low
$0.75
Volume
1,17,599
Beta
1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Prelude Therapeutics Incorporated share price today?
- Prelude Therapeutics Incorporated (PRLD) last traded around $4.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PRLD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PRLD. Download the app for real-time alerts.
- How can I analyze Prelude Therapeutics Incorporated stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.